Impact Study: MK-0646 (Dalotuzumab), Insulin Growth Factor 1 Receptor Antibody Combined with Pemetrexed and Cisplatin in Stage IV Metastatic Non-squamous Lung Cancer

por Huang, Chao H., Williamson, Stephen K., Neupane, Prakash, Taylor, Sarah A., Allen, Ace, Smart, Nora J., Uypeckcuat, Adelina M., Spencer, Sarah, Wick, Jo, Smith, Holly, Van Veldhuizen, Peter J., Kelly, Karen
Publicado 2016